Siemans and AES MADE Fluence together and are major shareholders
GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
Fluence Energy, Inc. (NASDAQ:FLNC) should definitely note that the Director, Julian Jose Marquez, recently paid US$17.00 per share to buy US$204k worth of the stock. We reckon that's a good sign, especially since the purchase boosted their holding by 150%.
The Last 12 Months Of Insider Transactions At Fluence Energy
The Independent Chair of the Board of Directors Herman Bulls made the biggest insider purchase in the last 12 months. That single transaction was for US$280k worth of shares at a price of US$28.00 each.
While Fluence Energy insiders bought shares during the last year, they didn't sell. They paid about US$15.34 on average.
The Last 12 Months Of Insider Transactions At Fluence Energy
The Independent Chair of the Board of Directors Herman Bulls made the biggest insider purchase in the last 12 months. That single transaction was for US$280k worth of shares at a price of US$28.00 each.
While Fluence Energy insiders bought shares during the last year, they didn't sell. They paid about US$15.34 on average.
These cancer drugs all have a myriad of potential side effects though, right?Oh that one -- very toxic. It doesn't cure cancer it's just for infections and for less infection you get--
YOUR SPLEEN RUPTURED!>
Spleen rupture
Acute Respiratory Distress Syndrome (ARDS)- Oh good that's fun
- Splenic rupture, including fatal cases, may occur following administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) products. Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture.
Severe allergic reactions - Why Not!
- ARDS may occur in patients receiving rhG-CSF products. Evaluate patients who develop fever, pulmonary infiltrates, or respiratory distress. Discontinue ROLVEDON in patients with ARDS.
Sickle cell crisis in patients with sickle cell disorders
- Serious allergic reactions, including anaphylaxis, may occur in patients receiving rhG-CSF products. Permanently discontinue ROLVEDON in patients who experience severe allergic reactions.
Glomerulonephritis- I have no idea but bring it on!
Leukocytosis
- Glomerulonephritis has occurred in patients receiving rhG-CSF products. Diagnoses were based on azotaemia, hematuria (microscopic and macroscopic), proteinuria and renal biopsy. Events of glomerulonephritis generally resolved after dose reduction or discontinuation. Evaluate and consider dose reduction or discontinuation of ROLVEDON if causality is likely.
Thrombocytopenia
Capillary leak syndrome-> of course!
Potential for tumor growth-stimulating effects on malignant cells<-- WHAT!!!!!!
- Capillary leak syndrome has been reported following administration of rhG-CSF products and is characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration. Episodes vary in frequency and severity and can be life-threatening if treatment is delayed. If symptoms develop, monitor closely and provide standard symptomatic treatment, which may include the need for intensive care.
Christ no infection but sorry your breast cancer is much worse now....
- The granulocyte colony-stimulating factor (G-CSF) receptor through which ROLVEDON works has been found on tumor cell lines. The possibility that ROLVEDON acts as a growth factor for any tumor type, including myeloid malignancy and myelodysplasia, diseases for which ROLVEDON is not approved, cannot be excluded.
Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with breast and lung cancer
Aortitis
Nuclear imaging
- Aortitis has been reported in patients receiving rhG-CSF products. It can occur as early as the first week after starting treatment. Consider aortitis in patients who develop generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and elevated inflammatory markers (eg, c-reactive protein and white blood cell count) without known etiology. Discontinue ROLVEDON if aortitis is suspected.
Side effects
back pain too... no.
- The most common adverse reactions (≥20%) were fatigue, nausea, diarrhea, bone pain, headache, pyrexia, anemia, rash, myalgia, arthralgia, and back pain.
I tried to figure out what the TAM was for this thing, I couldn't find any estimates.
The stock was below $0.75 recently, had it not been for that and near a bottom of $1.40, I would say "well, there's no way this FDA approval can hurt it"... but that's not the case.
Now, there is one thing I read, and I can't find it now, but it was on one of those scientific websites... that since this one got approved, (it implied) that the one you mentioned above is looking good too. Apparently they are based on the same .... whatever the particular molecular action is.... and don't ask me how this stuff works... but however this one does it, it portends well for the one above that you mentioned. The writer seemed to think the TAM on it is huge. Note.... this was a scientific website behind a paywall. The type bio-tech analysts pay to read. The savant of course has the work-around on those. I've posted the "how to" in chit-chat several times over the years.
So I dunno Stoney. Like I said, whales never sleep and the fact that it wasn't up more even on a Friday ah's.... leaves me reticent. I already said that. We'll see what the pre-market looks like. Herd mindset alone on an FDA approval can be good for a 40% pop in the pre-market to the nimble player... whether the drug has side effects or not.
To quote a dozen plus emails over the last 6 months... "we don't care, we want the quick scalp."
#1 for a reason Stoney.
"we don't care, we want the quick scalp."
The last words many a soldier heard in the old days.....
--Fortuna Silver Mines provides update on Seguela gold project exploration 05:05 FSM
--Darling Ingredients initiated with a Buy at Stifel 05:16 DAR Stifel analyst Derrick Whitfield initiated coverage of Darling Ingredients with a Buy rating and $101 price target. The company controls 15% of the world's waste fats and greases and its management team is widely regarded as industry leaders, Whitfield tells investors in a research note. The analyst says the company's scale and experience "make it a natural consolidator of the highly fragmented rendering market," allowing it to enhance feedstock security and benefit from a rising price environment for waste fats/greases.
--Terran Orbital initiated with a Buy at B. Riley 05:18 LLAP
--Borr Drilling reinstated with a Buy at DNB Markets 05:26 BORR
--Carpenter Technology upgraded to Outperform from Market Perform at Cowen 05:45 CRS Cowen analyst Gautam Khanna upgraded Carpenter Technology to Outperform from Market Perform with a $45 price target. The recent pullback in the shares provides an attractive entry point, Khanna tells investors in a research note. The analyst sees accelerating earnings gains and a "catalyst-rich backdrop" with 787, 737 and A320 rate hikes as well as the investor day. %). Lead times in Carpenter's "high margin" aero engine products are greater than 40 weeks, Khanna points out.
--Dakota Gold initiated with a Speculative Buy at Canaccord 05:53 DC Canaccord analyst Michael Fairbairn initiated coverage of Dakota Gold with a Speculative Buy rating and $5.25 price target.
--RH price target raised to $328 from $300 at Barclays
The last words many a soldier heard in the old days.....
--Fortuna Silver Mines provides update on Seguela gold project exploration 05:05 FSM
--Darling Ingredients initiated with a Buy at Stifel 05:16 DAR Stifel analyst Derrick Whitfield initiated coverage of Darling Ingredients with a Buy rating and $101 price target. The company controls 15% of the world's waste fats and greases and its management team is widely regarded as industry leaders, Whitfield tells investors in a research note. The analyst says the company's scale and experience "make it a natural consolidator of the highly fragmented rendering market," allowing it to enhance feedstock security and benefit from a rising price environment for waste fats/greases.
--Terran Orbital initiated with a Buy at B. Riley 05:18 LLAP
--Borr Drilling reinstated with a Buy at DNB Markets 05:26 BORR
--Carpenter Technology upgraded to Outperform from Market Perform at Cowen 05:45 CRS Cowen analyst Gautam Khanna upgraded Carpenter Technology to Outperform from Market Perform with a $45 price target. The recent pullback in the shares provides an attractive entry point, Khanna tells investors in a research note. The analyst sees accelerating earnings gains and a "catalyst-rich backdrop" with 787, 737 and A320 rate hikes as well as the investor day. %). Lead times in Carpenter's "high margin" aero engine products are greater than 40 weeks, Khanna points out.
--Dakota Gold initiated with a Speculative Buy at Canaccord 05:53 DC Canaccord analyst Michael Fairbairn initiated coverage of Dakota Gold with a Speculative Buy rating and $5.25 price target.
--RH price target raised to $328 from $300 at Barclays
--Deere invests billions in smart crop sprayers, self-driving tractors, WSJ says
Van we had the idea --> robot tractors!
Lots of Bio releases today due to conferences weeding through them all these 2 stand out-
--Mersana Therapeutics announces FDA Fast Track designation to XMT-1660 08:11 MRSN Mersana Therapeutic
A) Mersana Therapeutics, Inc. (MRSN)- GUMMY
NasdaqGS - NasdaqGS Real Time Price.
7.80-0.19(-2.38%)
At close: September 9 04:00PM EDT
8.40+0.60(+7.69%)<-----------------------
Pre-Market:08:19AM EDT
--Can-Fite : New psoriasis data showing "superior' safety & efficacy presented 07:07 CANF
B) Can-Fite BioPharma Ltd. (CANF)- Watch
NYSE American - Nasdaq Real Time Price.
0.9282+0.0388(+4.36%)
At close: September 9 04:00PM EDT
0.9659+0.04(+4.06%)
Pre-Market:08:13AM EDT
Van we had the idea --> robot tractors!
Lots of Bio releases today due to conferences weeding through them all these 2 stand out-
--Mersana Therapeutics announces FDA Fast Track designation to XMT-1660 08:11 MRSN Mersana Therapeutic
A) Mersana Therapeutics, Inc. (MRSN)- GUMMY
NasdaqGS - NasdaqGS Real Time Price.
7.80-0.19(-2.38%)
At close: September 9 04:00PM EDT
8.40+0.60(+7.69%)<-----------------------
Pre-Market:08:19AM EDT
--Can-Fite : New psoriasis data showing "superior' safety & efficacy presented 07:07 CANF
B) Can-Fite BioPharma Ltd. (CANF)- Watch
NYSE American - Nasdaq Real Time Price.
0.9282+0.0388(+4.36%)
At close: September 9 04:00PM EDT
0.9659+0.04(+4.06%)
Pre-Market:08:13AM EDT
If MRSN sounds familiar it's because we have gummied this in the past on 8/8 the stock roared from $5.00 to $7.80 on this news-
Looks like next leg up--
Mersana to get $100M upfront fee from GSK for co-commercialization of XMT-2056 08/08 MRSN, GSK Mersana Therapeutics (MRSN) announced a global collaboration that provides GSK (GSK) an exclusive option to co-develop and commercialize XMT-2056, an Immunosynthen ADC that targets a novel epitope of HER2. XMT-2056 is designed to activate the innate immune system through STING signaling in both tumor-resident immune cells and in tumor cells."GSK brings highly complementary development and commercial capabilities, a wealth of immuno-oncology experience, a deep knowledge of the STING pathway and a shared vision for XMT-2056's broad potential," said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. "We believe this agreement solidifies Mersana's position as a partner of choice during this momentous period in the ADC space and serves as validation for our Immunosynthen platform, which takes ADCs beyond the cytotoxic realm by enabling a targeted stimulation of the innate immune system. Additionally, the agreement structure demonstrates our ability to generate meaningful non-dilutive capital upfront to support the development of our innovative candidates while also providing the potential for meaningful downstream economics." In preclinical models, XMT-2056 demonstrated robust anti-tumor activity as a monotherapy in both HER2-high and HER2-low expressing models, and enhanced efficacy has been shown when used in combination with multiple approved agents, including trastuzumab, pertuzumab, anti-PD-1, or trastuzumab deruxtecan. Preclinical data also suggest that XMT-2056 has the potential to enable immunological memory for prolonged anti-tumor activity. Mersana expects to initiate a Phase 1 clinical trial of XMT-2056 to investigate its potential in a range of HER2-expressing tumors such as breast, gastric and non-small-cell lung cancers. The U.S. Food and Drug Administration recently granted an orphan drug designation to XMT-2056 for the treatment of gastric cancer.Under the terms of the agreement, Mersana will receive an upfront option purchase fee of $100M. Mersana also is eligible to receive up to $1.36B in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option. Show Related Items >>
Looks like next leg up--
Mersana to get $100M upfront fee from GSK for co-commercialization of XMT-2056 08/08 MRSN, GSK Mersana Therapeutics (MRSN) announced a global collaboration that provides GSK (GSK) an exclusive option to co-develop and commercialize XMT-2056, an Immunosynthen ADC that targets a novel epitope of HER2. XMT-2056 is designed to activate the innate immune system through STING signaling in both tumor-resident immune cells and in tumor cells."GSK brings highly complementary development and commercial capabilities, a wealth of immuno-oncology experience, a deep knowledge of the STING pathway and a shared vision for XMT-2056's broad potential," said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. "We believe this agreement solidifies Mersana's position as a partner of choice during this momentous period in the ADC space and serves as validation for our Immunosynthen platform, which takes ADCs beyond the cytotoxic realm by enabling a targeted stimulation of the innate immune system. Additionally, the agreement structure demonstrates our ability to generate meaningful non-dilutive capital upfront to support the development of our innovative candidates while also providing the potential for meaningful downstream economics." In preclinical models, XMT-2056 demonstrated robust anti-tumor activity as a monotherapy in both HER2-high and HER2-low expressing models, and enhanced efficacy has been shown when used in combination with multiple approved agents, including trastuzumab, pertuzumab, anti-PD-1, or trastuzumab deruxtecan. Preclinical data also suggest that XMT-2056 has the potential to enable immunological memory for prolonged anti-tumor activity. Mersana expects to initiate a Phase 1 clinical trial of XMT-2056 to investigate its potential in a range of HER2-expressing tumors such as breast, gastric and non-small-cell lung cancers. The U.S. Food and Drug Administration recently granted an orphan drug designation to XMT-2056 for the treatment of gastric cancer.Under the terms of the agreement, Mersana will receive an upfront option purchase fee of $100M. Mersana also is eligible to receive up to $1.36B in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option. Show Related Items >>
Abbreviated run through today because.....
Oh Van you know how to get at me... highlight the one stock i can't trade right...
There was an amazing articles a way back in the Times about all these mysterious coffee shops showing up in NYC trendy neighborhoods- They had a carefully researched name something like Blank Dot.. that's not it but they were popping up everywhere ans some locals did some digging and it's two cynical hedge fund dudes...
Just drenching the market with average coffee and only one barista that's their business plan use these annoying six cup Italian machines one employee -god help them during robberies- and so so coffee....
No thanks.
Just drenching the market with average coffee and only one barista that's their business plan use these annoying six cup Italian machines one employee -god help them during robberies- and so so coffee....
No thanks.